Business Development

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: Our client was advising principal investors on a possible transaction to cover the development and commercialization of a product targeting chemotherapy-induced anemia (CIA). Alacrita was...

Challenge: A UK investment company was considering leading an investment round in a UK-based platform technology company utilizing induced pluripotent stem cells (iPSCs) in disease models as R&D...

Challenge Our client was a privately-held US biotech company developing a proprietary platform technology for in vivo expression of DNA coding for a therapeutic antibody or protein. The approach...

Challenge: Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The asset in question was a...

Challenge One of the leading medical imaging companies worldwide approached Alacrita to assess an opportunity to acquire the manufacturing and distribution rights to an important imaging agent used...

Challenge Our client, a UK-based private equity company, was evaluating an investment in a full service global medical communications agency with a portfolio of blue-chip biopharma clients, and as...

Challenge: A pharma company was interested in identifying novel protein-based autoimmune / auto-inflammatory assets early in development from pre-GLP studies to 18 months from an IND. The company had...

Challenge: A phase 2 clinical-stage pharma company intent on supplementing their internal pipeline with external innovation asked Alacrita to identify immune-oncology or vaccine assets owned by...

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...